AU
UK
CA
US
IND
NZ
Last update at 2026-06-04T15:43:37.250619Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
Tue 01 Apr 25, 11:25 PMCOSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
Wed 19 Mar 25, 11:00 PMU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.02%
Tue 27 Aug 24, 09:35 PM| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -15.22500M | -4.37000M | 4.53M | 2.59M | 1.46M |
| Minority interest | - | - | - | - | - |
| Net income | -15.30900M | -3.48500M | 3.45M | 2.64M | 1.46M |
| Selling general administrative | 10.45M | 5.59M | 2.73M | 2.54M | 2.57M |
| Selling and marketing expenses | - | 0.03M | 0.02M | 0.04M | 0.09M |
| Gross profit | 6.80M | 2.94M | 8.56M | 8.21M | 5.98M |
| Reconciled depreciation | 1.61M | 1.44M | 1.47M | 1.48M | 1.44M |
| Ebit | -15.09600M | -4.23400M | 4.67M | 2.71M | 1.59M |
| Ebitda | -13.48900M | -2.79100M | 6.14M | 4.18M | 3.04M |
| Depreciation and amortization | 1.61M | 1.44M | 1.47M | 1.48M | 1.44M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -26.28097M | -4.62900M | 4.32M | 2.43M | 1.66M |
| Other operating expenses | 40.06M | 11.77M | 10.25M | 11.06M | 10.20M |
| Interest expense | 0.13M | 0.14M | 0.14M | 0.12M | 0.14M |
| Tax provision | 0.08M | -0.88500M | 1.08M | -0.05292M | 0.00000M |
| Interest income | 0.44M | 0.06M | 0.14M | - | - |
| Net interest income | 0.31M | -0.07700M | 0.00200M | -0.16226M | -0.18050M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.08M | -0.88500M | 1.08M | -0.05292M | 0.42M |
| Total revenue | 13.78M | 7.14M | 14.57M | 13.49M | 11.86M |
| Total operating expenses | 33.08M | 7.57M | 4.24M | 5.78M | 4.32M |
| Cost of revenue | 6.98M | 4.21M | 6.02M | 5.28M | 5.88M |
| Total other income expense net | 11.06M | 0.26M | 0.21M | 0.16M | -0.20330M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -15.30900M | -3.48500M | 3.45M | 2.64M | 1.46M |
| Net income applicable to common shares | - | - | - | - | - |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 35.07M | 23.75M | 27.80M | 24.35M | 22.92M |
| Intangible assets | - | 0.00700M | 0.00927M | 0.01M | 0.01M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.43M | 0.29M | 0.10M | 0.15M | 0.27M |
| Total liab | 21.91M | 2.71M | 4.01M | 2.61M | 3.85M |
| Total stockholder equity | 13.16M | 21.04M | 23.79M | 21.74M | 19.06M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 4.29M | 0.73M | 1.67M | 1.13M | 1.31M |
| Common stock | 22.49M | 13.52M | 12.30M | 12.99M | 12.95M |
| Capital stock | 22.49M | 16.72M | 16.69M | 16.56M | 16.51M |
| Retained earnings | -12.11000M | 4.36M | 8.02M | 5.08M | 2.44M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | 0.00000M | 0.00000M |
| Cash | 16.39M | 6.68M | 10.18M | 6.10M | 4.21M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 7.22M | 1.31M | 7.04M | 7.76M | 4.74M |
| Current deferred revenue | 0.12M | - | 2.95M | 4.81M | 2.19M |
| Net debt | -14.08300M | -4.98000M | -8.24636M | -4.02509M | -1.87991M |
| Short term debt | 0.27M | 0.60M | 0.39M | 0.36M | 0.25M |
| Short long term debt | - | - | - | - | 0.07M |
| Short long term debt total | 2.31M | 1.70M | 1.93M | 2.08M | 2.33M |
| Other stockholder equity | 4.27M | 3.16M | 3.47M | 3.67M | 3.67M |
| Property plant equipment | - | - | - | - | - |
| Total current assets | 23.98M | 11.27M | 15.17M | 9.73M | 7.10M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | - | - |
| Short term investments | - | - | - | - | - |
| Net receivables | 2.47M | 0.29M | 2.13M | 1.68M | 1.66M |
| Long term debt | - | - | - | - | - |
| Inventory | 2.69M | 4.01M | 2.77M | 0.07M | 0.95M |
| Accounts payable | 2.41M | 0.28M | - | - | - |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1.48300M | 4.35M | 4.12M | 4.40M | 11.36M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.12M | 0.75M | 0.69M | 0.66M | 0.54M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 11.09M | 12.48M | 12.63M | 14.62M | 15.82M |
| Capital lease obligations | 2.31M | 2.25M | 2.62M | 2.65M | 2.90M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | 25.08M | -0.73000M | -0.38882M | -0.79070M | -0.48414M |
| Change to liabilities | - | - | - | - | - |
| Total cashflows from investing activities | 25.08M | -0.73000M | -0.30400M | -0.62015M | -0.37967M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | -0.58800M | -0.35700M | -0.26700M | 50.59M | 21.55M |
| Change to operating activities | - | - | - | - | - |
| Net income | -15.30900M | -3.48500M | 3.45M | 2.64M | 1.46M |
| Change in cash | 9.71M | -3.51200M | 4.03M | 1.89M | 2.75M |
| Begin period cash flow | 6.68M | 10.19M | 6.16M | 4.21M | 1.46M |
| End period cash flow | 16.39M | 6.68M | 10.19M | 6.10M | 4.21M |
| Total cash from operating activities | -14.56800M | -2.58200M | 5.23M | 2.75M | 3.49M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 1.61M | 1.47M | 1.47M | 1.48M | 1.44M |
| Other cashflows from investing activities | 0.21M | -0.00800M | - | -0.06416M | 0.11M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 1.59M | -1.16987M | -1.05582M | -0.87372M | 1.24M |
| Change to account receivables | -2.41963M | 1.79M | -0.61500M | -0.13778M | 1.24M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | -0.00802M | 0.01M | 0.06M | 0.02M | 0.00384M |
| Change to netincome | - | - | - | - | - |
| Capital expenditures | 1.16M | 0.72M | 0.01M | 0.56M | 0.49M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -1.67491M | 0.06M | -0.93600M | -1.15873M | 0.47M |
| Stock based compensation | 0.46M | 0.19M | 0.07M | 0.01M | 0.11M |
| Other non cash items | 0.27M | 0.10M | 0.10M | 0.00519M | 0.02M |
| Free cash flow | -15.72900M | -3.30400M | 4.92M | 2.20M | 3.01M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CSCI COSCIENS Biopharma Inc. |
- -% | - | - | - | 0.92 | 1.17 | 0.14 | 3.33 |
| NVO Novo Nordisk A/S |
2.31 5.51% | 44.31 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.78 4.23% | 44.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
14.76 3.44% | 443.10 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
6.86 1.11% | 625.81 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce inflammation for the healthcare and cosmetic industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as for endocrinology and oncology indications. The company sells its products through its distribution network. It has license agreements with Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd, as well as Agriculture Canada and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
222 Bay Street, Toronto, ON, Canada, M5K 1E7
| Name | Title | Year Born |
|---|---|---|
| Mr. Giuliano La Fratta | Senior VP of Finance & CFO | NA |
| Mr. Michel Regnier P. Eng. | Senior VP of Technical operations, MD of Ceapro Inc. & CTO | NA |
| Dr. Michael Teifel Ph.D. | Senior Vice President of GmbH & Chief Scientific Officer | NA |
| Dr. Matthias Gerlach | Senior Vice President Manufacturing and Supply Chain & Head of Production | NA |
| Ms. Anna Elizabeth Biehn | Chief Executive Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...